Our History

In the fast-growing metroplex of Phoenix, Arizona, we formed Calviri in 2017 to end cancer. This was made feasible by our discovery of an unappreciated, yet fundamental, molecular characteristic of all tumors that distinguishes them from healthy host cells. To leverage this discovery, we invented technologies that merge biology with semiconductor chips.

These research and development efforts provided the means for diagnostics and vaccines that are unlike any others. Today, we are focused on commercializing our canine multi-cancer tests accurately detect stage 1 disease, that can be treated with our early-stage therapeutic vaccines. Tomorrow, our products will be include vaccines to prevent cancers from starting. We are determined to globally provide diagnostics and vaccines for both dogs and people that will end cancer.